Coronavirus (COVID-19) Collection
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infectionSince December 2019, COVID-19 caused by SARS-CoV-2 has spread worldwide (Hayakawa et al., 2020). As of January 25th, 2022, 544 re-infected COVID-19 cases have been reported worldwide (BNO news. 2022; Inada et al., 2021).
Antimicrobial Use Fell Substantially in Japan in 2020—The COVID-19 Pandemic May Have Played a RoleThe COVID-19 outbreak in China at the end of 2019 had spread to Japan by early 2020. The surge in infected cases may have precipitated behavioral changes among physicians and patients, including increased unnecessary antimicrobial use (AU) that could promote antimicrobial resistance (AMR).
A case of varicella zoster virus meningitis following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patientSince December 2019, COVID-19, caused by SARS-CoV-2 infection, has been a major health threat worldwide (Hayakawa et al., 2020). The mRNA-based BNT162b2 mRNA COVID-19 vaccine has demonstrated a high efficacy rate with an acceptable safety profile (Polack et al., 2020). In Japan, a nationwide mass BNT162b2 mRNA vaccination campaign was launched and rolled out at an exceptionally rapid pace with high vaccine acceptance. As of June 13, 2021, 14.0% (n=17 580 587) and 4.9% (n=6 104 732) of the population had received their first and second vaccine dose, respectively (Ministry of Health, Labour and Welfare, Japan, 2021).
Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in JapanGlobally, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has affected more than 120 million individuals and caused 2.7 million deaths (Roser et al., 2021). As of 23 March 2021, there have been 457,754 cases and 8861 deaths in Japan (Ministry of Health, Labour and Welfare, 2021), which is lower than the number of cases and deaths reported in other countries with outbreaks of COVID-19 (Roser et al., 2021).
Clinical course of alopecia after COVID-19A 49-year-old man was admitted to our hospital in late March 2020, 6 days after onset of coronavirus disease 2019 (COVID-19). He received remdesivir in a clinical study. Oxygen supplementation was not required. Defervescence occurred 12 days after onset, and he was discharged 21 days after symptom onset. In mid-May 2020, he noticed alopecia on his head. He started taking self-imported minoxidil 5 mg/day and finasteride 1 mg/day in June 2020, and was still taking these medications at the time of writing.